Skip to main content

Table 2 Effect of HBV and HCV co-infections on death among HIV patients who initiated ART between 2010 and 2018 in Guangxi, China

From: Treatment outcomes of HIV patients with hepatitis B and C virus co-infections in Southwest China: an observational cohort study

Coinfection Number of HIV patients Deaths Person-years (PY) Mortality rate per 100 person-years (95% CI) HR (95% CI) P value aHRa (95% CI) P value
Total 58,239 6,916 234,421.19 2.95 (2.88–3.02)     
HIV only 46,847 5,366 187,680.8 2.86 (2.78–2.93) Reference   Reference  
HIV + HBV 6,707 797 28,092.09 2.84 (2.65–3.03) 0.99 (0.92–1.07) 0.784 1.42 (1.32–1.54)  < 0.001
HIV + HCV 3,828 590 15,148.30 3.89 (3.59–4.20) 1.35 (1.24–1.47)  < 0.001 1.65 (1.47–1.86)  < 0.001
HIV + HBV + HCV 857 163 3,500.00 4.66 (3.96–5.35) 1.60 (1.37–1.87)  < 0.001 2.23 (1.87–2.66)  < 0.001
  1. CI, Confidence interval; HR, Hazard ratio; aHR, Adjusted hazard ratio; HBV, Hepatitis B virus; HCV, Hepatitis C virus; HIV, Human immunodeficiency virus
  2. aAdjusted for Age, gender, marital status, route of HIV transmission, CD4 count before ART, WHO clinical stage before ART, initial first-line ART regimen, current ART regimen, duration of using TDF-containing regimens, calendar year of ART initiation